Background. Sodium oxybate shares some pharmacological effects with alcohol, and has been approved for the treatment of alcohol dependence in Europe. This study evaluated the pharmacodynamic interactions of SMO.IR, a solid formulation of sodium oxybate and alcohol, to assess possible synergism, potentiation or antagonism of SMO.IR and alcohol. Methods. 24 healthy volunteers participated in a double-blind crossover trial. Study participants randomly received: SMO.IR alone, alcohol alone, SMO. IR + alcohol, and double placebo. Study endpoints were objective and subjective cognitive tests, adverse events, vital signs assessed before, and 15 and 165 minutes after study drug administration. Cognitive tests included: Body Sway Test, Saccadic Eye Movement, Choice Reaction Time, Critical Tracking Test, Digit Vigilance, Numeric and, Spatial Working Memory, Bond & Lader VAS, ARCI 49, and Biphasic Alcohol Effects Scale. Results. Alcohol produced a significant impairment in cognitive performance and subjective sedation at 15 min. SMO.IR-induced less pronounced objective and subjective sedation 165 min post dose. There was a significant interaction between SMO.IR and alcohol, at 15 min, with an increase in alertness and stimulation and a decrease in sedation. An isolated mild decrease in digit vigilance accuracy was observed at 165 minutes post dose with the combination. The combination increased the number of treatment-emergent adverse events: [2005] [2006] [2007] . The primary outcomes of the study were: the drug antiwithdrawal effects; the drug effects on relapse prevention, the treatment drop out rate; while the secondary outcomes were: the drug side effects and adverse reactions, the appetive behavour ("misuse"), the drug abuse and the overdose, intoxication and withdrawal episodes. Finally, the study evaluated, for the first time, in a large cohort of Italian alcoholics, the prevalence of both infection diseases (e.g. hepatitis C, HIV, ect.) and prevalent psychiatric illness (including personalities disorders).
Findings. The study confirmed the effectiveness of Sodium Oxybate in suppressing withdrawal syndrome (81% of the subjects treated were successfully rehabilitated) and in maintaining abstinence (76% and 78% of patients were abstinent at six and twelve months after starting treatment). The study showed that the drug is also safe and manageable, especially if used in doses between 50 and 100 mg/kg/die (the average dose was between 78.11 + 22.30 mg/kg/ die). Misuse and abuse were limited (12% of treatments), cases of intoxication an overdose extremely rare. For the first time in Italy, the study helped to identify the main demographics and clinical features of a significant sample of alcoholics subjects treated with Sodium Oxybate and the prevalence of prevalent infections diseases (31 % were HBcAb + HBsAg positive, 15% were HCV positive and 4% were HIV positive) and psychiatric illnesses (12% in Axis I and 4% in Axis II).
Interpretation. The GUM study confirms the effectiveness and the safety of Sodium Oxybate in the treatment of subjects undergoing rehabilitation in Italian alcohol treatment centers. Funding: Laboratorio Farmaceutico CT S.r.l. Previously, we observed that short exposure to 20mM ethanol upregulated miR-9 in primary rodent neuronal cultures or brain organotypic slices. These observations prompted us to perform more detailed temporal characteristics and dose-dependence of miR-9 response to ethanol using a regimen of ethanol exposures and withdrawals. We used two physiologically-relevent ethanol concentrations 20 mM and 50 mM. Exposure and/or withdrawal ranged from 15 minutes to 24 hours. We used postnatal day 5 striatal medium spiny neurons harvested from C57BL/6 mice. Total RNA and small RNA fraction (<200 nt) were isolated and treated with DNase. Concentrations of mature mmu-miR-9, miR-9* and miR-9 precursors: pre-miR-9-1, -9-2, and -9-3 were determined by qRT-PCR. Preliminary results indicate that exposure to 20 mM but not 50 mM ethanol for 15 min caused an almost 2-fold increase in miR-9 expression. Interestingly, the expression of pre-mir-9-1 was also increased in response to ethanol. We are currently testing ethanol effect on expression of pre-miR-9-2 and -9-3 precursors. We are also trying to understand interplay between genetic (SNPs) and epigenetic (DNA methylation) mechanisms on regulation of expression of mir-9 genes by ethanol. We performed sequencing of promoters of mir-9 genes using human samples and observed presence of several SNPs in these regions. Chronic alcoholism is a significant worldwide reason for brain/synaptic damage and mild-to-moderate cognitive impairment, but the mechanisms are unresolved. In that regard, repetitive, subchronic binge ethanol exposure with adult rats and rat organotypic brain cultures triggers neuroinflammatory routes leading to oxidative stress and regional neurodegeneration. Our results indicate excessive arachidonic acid (AA) mobilization due to increased phospholipase A2 (PLA2) levels/activity, and this appears related to elevations in astroglial aquaporin-4 (AQP4) and brain edema. Furthermore, inhibiting AQP4 is neuroprotective. A promising sensor for the binge ethanol which could be triggering downstream AQP4 and PLA2 elevations is nuclear poly(ADP-ribose) polymerase-1 (PARP1), also potentiated by ethanol. Indeed, blocking PARP1 activity with PJ34 reduces binge ethanol-induced neurotoxicity, which implies that a component of the process is necroptotic or "parthanatotic" in nature. Furthermore, omega-3 docosahexaenoic acid (DHA 22:6) administration significantly suppresses PARP1, AQP4 and PLA2 elevations, AA release, and neurodamage. Details regarding the PLA2 isoforms involved and insights into DHA's mechanism of neuroprotection will be presented. Other laboratories have reported that chronic ethanol treatments increase toll-like receptors/ ligands, proinflammatory cytokines and NADPH oxidase; we suggest that those neuroimmune pathways interact via cross-talk with PARP1-AQP4-PLA2-AA cascades in order to augment oxidative stress as well. Supported by USPHS UO1 AA018279 and the Loyola Univ. Alcohol Research Program. This paper describes a new experimental procedure of alcohol drinking promoting exceptionally high intakes of alcohol in Sardinian alcohol-preferring (sP) rats (one of the few rat lines selectively bred worldwide for excessive alcohol consumption). sP rats were exposed to the 4-bottle "alcohol (10%, 20%, and 30%, v/v) vs water" choice regimen during one of the 12 hours of the dark phase of the daily light/dark cycle; the time of alcohol exposure was changed daily under a semi-random order and was unpredictable to rats. Alcohol intake was found to be highly positively correlated (n = 24, r = 0.984, P < 0.0001) with the time of alcohol exposure and ranged from an average of 0.86 ± 0.06 g/kg (drinking session occurring during the 1st hour of the dark phase) to an average of 2.00 ± 0.07 g/kg (drinking session occurring during the 12th hour of the dark phase). Alcohol drinking during the 12th hour of the dark phase resulted in (a) blood alcohol levels averaging 101.1 ± 8.1 mg% and (b) severe signs of alcohol intoxication (e.g., markedly impaired performance at a Rota-Rod task). These results demonstrate that unpredictable, limited access to multiple alcohol concentrations may result in exceptionally high intakes of alcohol in sP rats. A progressively increasing emotional "distress" associated to the rats' expectation of alcohol might be the neurobiological basis of this behavior.
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O1.3 BINGE-LIKE DRINKING IN SARDINIAN ALCOHOL-PREFERRING RATS EXPOSED TO AN UNPREDICTABLE SCHEDULE OF LIMITED ACCESS TO MULTIPLE ALCOHOL CONCENTRATIONS
Supported by NIAAA-funded "Integrative Neuroscience Initiative on Alcoholism" (INIA-Stress) Consortium.
O1.4 REHABILITATION AND NEUROPROTECTION: USE OF EXERCISE AND ENVIRONMENT IN FAS (MODEL)
A. Klintsova Department of Psychology, University of Delaware, Newark, DE, United States Prenatal alcohol exposure in humans can result in a wide range of deficits collectively referred to as Fetal Alcohol Spectrum Disorders (FASD). Impairments vary with degree and timing of alcohol exposure and include anatomical, behavioral and cognitive effects that persist into adulthood and are accompanied by structural changes. In rodent models of FASD, exposure to alcohol during the development produces significant damage to several brain regions, including the hippocampus and prefrontal cortex (PFC). In the adult hippocampal dentate gyrus (DG), the process of generating new neurons is affected. In addition, overall decrease in frontal brain size and reduced medial PFC pyramidal neuron dendritic complexity (Rasmussen, 2005) indicate damage to cortical areas. Using a rodent model of binge drinking during third trimester equivalent, we explored therapeutic effects of exercise alone and exercise followed by exposure to environmental complexity (EC) on neuroanatomical parameters (adult neurogenesis in DG, dendritic complexity of postmitotic doublecortin-positive cells in the DG and dendritic complexity of pyramidal neurons in mPFC) and on behavioral outcomes. Following postnatal alcohol exposure, rats were assigned to cages with running wheel or standard housing from PD30-42, followed by exposure to EC (PD42-72) after wheel-running. Animals were tested on learning behavior and brains were collected for neuroanatomy. Our data indicates that 1) exercise alone is not sufficient to rescue the alcohol-induced deficits; 2) a "super" combination of exercise followed by EC is more effective in promoting new cell survival and dendritic reorganization; and 3) behavioral (learning) deficits could be reversed by the "super" therapy. Conclusion. Drinking status at any time is essentially affected by previous period consumption: At long term, a strict continuous abstinence is much more effective than drinking reduction. The effect of acamprosate increases at every period, compensates the deterioration of drinking outcomes in time, and remains the same, irrespective of relapse occurrence during the previous period. We conclude that, after a patient's return to drinking, treatment with acamprosate should be continued. Furthermore, due to the high-observed autocorrelation inducing the mediating effects of previous periods, our results suggest that continuing the treatment has a cumulative therapeutic effect likely to exceed effect sizes demonstrated in clinical trials.
